News & Updates
Filter by Specialty:
T(11;14) translocation not linked to worse outcomes in multiple myeloma
In patients with multiple myeloma (MM), the chromosome translocation t(11;14) does not seem to be associated with worse prognosis, resulting in similar treatment outcomes as other standard-risk subgroups, reports a recent study.
T(11;14) translocation not linked to worse outcomes in multiple myeloma
15 Apr 2022
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
14 Apr 2022
High blood pressure, Scarff Bloom-Richardson grade 3 predict CV events in breast cancer
Pre-existing cardiovascular disease (CVD) and grade 3 Scarff Bloom-Richardson are associated with the occurrence of cardiovascular (CV) events among women with breast cancer, reports a study.
High blood pressure, Scarff Bloom-Richardson grade 3 predict CV events in breast cancer
13 Apr 2022
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
Both surgery and use of stereotactic body radiation therapy (SBRT) result in a decrease in the mean tumour size of early-stage nonsmall cell lung cancer (NSCLC), a recent study has shown.
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
12 Apr 2022
First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer
First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.